David Arterburn's main research focus is on finding safe, effective, and innovative ways to treat obesity. He is a general internist and health services researcher with a passionate commitment to helping individuals and families make treatment decisions that align with their values while sustaining their health over the long haul.
A national leader in obesity research, Dr. Arterburn joined Group Health Research Institute (GHRI) in 2006 to forge a new program of research spanning behavioral, pharmaceutical, and bariatric surgical care. Before joining GHRI, he published important findings on the epidemic nature and rising cost of obesity in the United States. Because tackling the obesity crisis requires a menu of treatment options, Dr. Arterburn's current research covers a broad range, including policy-level interventions for health plans, pharmaco-epidemiology, pharmacogenetics, the long-term outcomes of bariatric surgery, and shared decision making related to elective surgery. With the support of the Informed Medical Decisions Foundation, for which he serves as a medical editor, he has collaborated with Group Health's specialty leadership to implement and evaluate a new initiative to promote shared decision making around elective surgical care with video-based patient decision aids. The approach shows great promise for simultaneously improving the quality and lowering the costs of health care.
Dr. Arterburn's prior research in obesity pharmacotherapy has had a significant impact on clinical practice guidelines issued by the Department of Veterans Affairs (VA), the U.S. Preventive Services Task Force, the Agency for Healthcare Research and Quality, and the American College of Physicians. Dr. Arterburn is past chair of the Adult Obesity Measurement Advisory Panel sponsored by the National Committee on Quality Assurance, founding chair of the Obesity Society's Health Services Research Section, and past chair of Health Care Systems Research Network (HCSRN)'s Obesity Special Interest Group. He is also an affiliate associate professor in the University of Washington (UW) Department of Medicine. Dr. Arterburn is excited to continue his multidisciplinary work with these and other colleagues from the HCSRN, the UW, and the VA.
Bariatric surgery; health services research; economics and risk adjustment; pharmaceutical outcomes research
Obesity prevention and control
Pharmaco-epidemiology, pharmacogenetics, pharmaceutical outcomes research
Shared decision making
Coleman KJ, Haneuse S, Johnson E, Bogart A, Fisher D, O'Connor PJ, Sherwood NE, Sidney S, Theis MK, Anau J, Schroeder EB, O'Brien R, Arterburn D. Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care. 2016 Jun 6. pii: dc160194. [Epub ahead of print]. PubMed
Arterburn D, McCulloch D. Bariatric Surgery for Type 2 Diabetes: Getting Closer to the Long-term Goal. JAMA. 2016;315(12):1276-7. doi: 10.1001/jama.2016.1884. PubMed
Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, Bock SN, Landers JT, Kratz M, Foster-Schubert KE, Flum DR. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016 Mar 17. [Epub ahead of print]. PubMed
Deen JF, Krieger EV, Slee AE, Arslan A, Arterburn D, Stout KK, Portman MA. Metabolic Syndrome in Adults With Congenital Heart Disease. LID - 10.1161/JAHA.114.001132 [doi] LID - e001132 [pii] J Am Heart Assoc. 2016 Feb 12;5(2). pii: e001132. doi: 10.1161/JAHA.114.001132. PubMed
Paolino AR, McGlynn EA, Lieu T, Nelson AF, Prausnitz S, Horberg MA, Arterburn DE, Gould MK, Laws RL, Steiner JF. Building a Governance Strategy for CER: The Patient Outcomes Research to Advance Learning (PORTAL) Network Experience. EGEMS (Wash DC). 2016 Mar 28;4(2):1216. doi: 10.13063/2327-9214.1216. eCollection 2016. PubMed
Dr. Arterburn linked even short-term diabetes remission to less risk for microvascular kidney, eye, and limb diseases
Read it in Healthy Findings.
Research at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression.
Read it in News and Events.
Study leader Dr. David Arterburn will use PCORnet, new national clinical research network, to speed results.
Read it in News and Events.
Seattle Times, Jan 6, 2015